SN BioScience's Innovative SNB-101 Receives FDA's Orphan Drug Designation for Gastric Cancer Treatment SN BioScience's SNB-101, a groundbreaking nanoparticle anticancer drug, has received Orphan Drug Designation from the FDA for gastric cancer, offering hope to patients.

SN BioScience's Innovative SNB-101 Receives FDA's Orphan Drug Designation for Gastric Cancer Treatment #South_Korea #Seongnam #SN_BioScience #Orphan_Drug #Nano_Drug

SNB-101: A Breakthrough Therapy for Small Cell Lung Cancer Gains Government Support The groundbreaking anticancer drug SNB-101 has gained significant support, being selected for Korea's 2025 Drug Development Project. This highlights its promise in treating small cell lung cancer.

SNB-101: A Breakthrough Therapy for Small Cell Lung Cancer Gains Government Support #South_Korea #cancer_therapy #Seongnam #SN_BioScience #SNB-101

SN BioScience Achieves Milestone with SNB-101’s Phase 2 IND Clearance from FDA SN BioScience has received FDA approval for SNB-101 to proceed with Phase 1b/2 trials, targeting small cell lung cancer patients in the U.S. market.

SN BioScience Achieves Milestone with SNB-101’s Phase 2 IND Clearance from FDA #United_States #SN_BioScience #SNB-101 #small_cell_lung_cancer #Seongnam-si